Leveraging protein quaternary structure to identify oncogenic driver mutations

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1471-2105

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Leveraging protein quaternary structure to identify oncogenic driver mutations ; volume:17 ; number:1 ; day:22 ; month:3 ; year:2016 ; pages:1-13 ; date:12.2016
BMC bioinformatics ; 17, Heft 1 (22.3.2016), 1-13, 12.2016

Creator: Ryslik, Gregory A.

Contributor: Cheng, Yuwei
Modis, Yorgo
Zhao, Hongyu
SpringerLink (Online service)

DOI: 10.1186/s12859-016-0963-3

URN: urn:nbn:de:1111-2016032814741

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 11:03 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Ryslik, Gregory A.
Cheng, Yuwei
Modis, Yorgo
Zhao, Hongyu
SpringerLink (Online service)

Other Objects (12)

Hochschulschrift

Oncogenic potential of rare RRAS2 mutations

Small molecule inhibitors of RAS proteins with oncogenic mutations

Proteomic alterations in extracellular vesicles induced by oncogenic PIK3CA mutations

Oncogenic and drug-sensitive RET mutations in human epithelial ovarian cancer

Accumulation of Oncogenic Mutations During Progression from Healthy Tissue to Cancer

Leveraging genetically simple traits to identify small-effect variants for complex phenotypes

Leveraging unstructured data to identify hereditary angioedema patients in electronic medical records

VaryMinions: leveraging RNNs to identify variants in variability-intensive systems’ logs

Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors

Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening

Vav1 mutations identified in human cancers give rise to different oncogenic phenotypes

Overexpression of wild type RRAS2, without oncogenic mutations, drives chronic lymphocytic leukemia

Hochschulschrift

Oncogenic potential of rare RRAS2 mutations

Small molecule inhibitors of RAS proteins with oncogenic mutations

Proteomic alterations in extracellular vesicles induced by oncogenic PIK3CA mutations

Oncogenic and drug-sensitive RET mutations in human epithelial ovarian cancer

Accumulation of Oncogenic Mutations During Progression from Healthy Tissue to Cancer

Leveraging genetically simple traits to identify small-effect variants for complex phenotypes

Leveraging unstructured data to identify hereditary angioedema patients in electronic medical records

VaryMinions: leveraging RNNs to identify variants in variability-intensive systems’ logs

Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors

Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening

Vav1 mutations identified in human cancers give rise to different oncogenic phenotypes

Overexpression of wild type RRAS2, without oncogenic mutations, drives chronic lymphocytic leukemia

Hochschulschrift

Oncogenic potential of rare RRAS2 mutations

Small molecule inhibitors of RAS proteins with oncogenic mutations

Proteomic alterations in extracellular vesicles induced by oncogenic PIK3CA mutations

Oncogenic and drug-sensitive RET mutations in human epithelial ovarian cancer

Accumulation of Oncogenic Mutations During Progression from Healthy Tissue to Cancer

Leveraging genetically simple traits to identify small-effect variants for complex phenotypes

Leveraging unstructured data to identify hereditary angioedema patients in electronic medical records

VaryMinions: leveraging RNNs to identify variants in variability-intensive systems’ logs

Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors

Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening

Vav1 mutations identified in human cancers give rise to different oncogenic phenotypes

Overexpression of wild type RRAS2, without oncogenic mutations, drives chronic lymphocytic leukemia

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Leveraging protein quaternary structure to identify oncogenic driver mutations

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Oncogenic potential of rare RRAS2 mutations

Small molecule inhibitors of RAS proteins with oncogenic mutations

Proteomic alterations in extracellular vesicles induced by oncogenic PIK3CA mutations

Oncogenic and drug-sensitive RET mutations in human epithelial ovarian cancer

Accumulation of Oncogenic Mutations During Progression from Healthy Tissue to Cancer

Leveraging genetically simple traits to identify small-effect variants for complex phenotypes

Leveraging unstructured data to identify hereditary angioedema patients in electronic medical records

VaryMinions: leveraging RNNs to identify variants in variability-intensive systems’ logs

Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors

Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening

Vav1 mutations identified in human cancers give rise to different oncogenic phenotypes

Overexpression of wild type RRAS2, without oncogenic mutations, drives chronic lymphocytic leukemia

Oncogenic potential of rare RRAS2 mutations

Small molecule inhibitors of RAS proteins with oncogenic mutations

Proteomic alterations in extracellular vesicles induced by oncogenic PIK3CA mutations

Oncogenic and drug-sensitive RET mutations in human epithelial ovarian cancer

Accumulation of Oncogenic Mutations During Progression from Healthy Tissue to Cancer

Leveraging genetically simple traits to identify small-effect variants for complex phenotypes

Leveraging unstructured data to identify hereditary angioedema patients in electronic medical records

VaryMinions: leveraging RNNs to identify variants in variability-intensive systems’ logs

Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors

Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening

Vav1 mutations identified in human cancers give rise to different oncogenic phenotypes

Overexpression of wild type RRAS2, without oncogenic mutations, drives chronic lymphocytic leukemia

Oncogenic potential of rare RRAS2 mutations

Small molecule inhibitors of RAS proteins with oncogenic mutations

Proteomic alterations in extracellular vesicles induced by oncogenic PIK3CA mutations

Oncogenic and drug-sensitive RET mutations in human epithelial ovarian cancer

Accumulation of Oncogenic Mutations During Progression from Healthy Tissue to Cancer

Leveraging genetically simple traits to identify small-effect variants for complex phenotypes

Leveraging unstructured data to identify hereditary angioedema patients in electronic medical records

VaryMinions: leveraging RNNs to identify variants in variability-intensive systems’ logs

Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors

Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening

Vav1 mutations identified in human cancers give rise to different oncogenic phenotypes

Overexpression of wild type RRAS2, without oncogenic mutations, drives chronic lymphocytic leukemia

Related objects

Reset password